---
title: "Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292044496.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-07T10:02:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292044496.md)
  - [en](https://longbridge.com/en/news/292044496.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292044496.md)
generator: "portal-rs"
---

# Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [How TRYNGOLZA Approval and New Equity Shelf At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story](https://longbridge.com/en/news/295401431.md)
- [BioMarin spends up to $490m for Alesta’s bone disease candidate](https://longbridge.com/en/news/296381315.md)
- [Fulcrum and Slate Medicines sign merger agreement](https://longbridge.com/en/news/296206650.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**